Dr. Reddy's Laboratories Management
Management criteria checks 3/4
Dr. Reddy's Laboratories' CEO is Erez Israeli, appointed in Apr 2018, has a tenure of 6.83 years. directly owns 0.039% of the company’s shares, worth ₹396.86M. The average tenure of the management team and the board of directors is 6.8 years and 3.1 years respectively.
Key information
Erez Israeli
Chief executive officer
₹197.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.04% |
| Management average tenure | 6.8yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Prospects Need A Boost To Lift Shares
Feb 12
With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
Dec 27Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹54b |
| Sep 30 2024 | n/a | n/a | ₹53b |
| Jun 30 2024 | n/a | n/a | ₹56b |
| Mar 31 2024 | ₹197m | n/a | ₹56b |
| Dec 31 2023 | n/a | n/a | ₹52b |
| Sep 30 2023 | n/a | n/a | ₹51b |
| Jun 30 2023 | n/a | n/a | ₹47b |
| Mar 31 2023 | ₹195m | n/a | ₹45b |
| Dec 31 2022 | n/a | n/a | ₹36b |
| Sep 30 2022 | n/a | n/a | ₹31b |
| Jun 30 2022 | n/a | n/a | ₹30b |
| Mar 31 2022 | ₹127m | n/a | ₹24b |
| Dec 31 2021 | n/a | n/a | ₹26b |
| Sep 30 2021 | n/a | n/a | ₹19b |
| Jun 30 2021 | n/a | n/a | ₹17b |
| Mar 31 2021 | ₹120m | n/a | ₹17b |
| Dec 31 2020 | n/a | n/a | ₹21b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹19b |
| Mar 31 2020 | ₹195m | ₹107m | ₹19b |
| Dec 31 2019 | n/a | n/a | ₹16b |
| Sep 30 2019 | n/a | n/a | ₹27b |
| Jun 30 2019 | n/a | n/a | ₹21b |
| Mar 31 2019 | ₹123m | n/a | ₹19b |
Compensation vs Market: Erez's total compensation ($USD2.27M) is above average for companies of similar size in the Indian market ($USD1.14M).
Compensation vs Earnings: Erez's compensation has been consistent with company performance over the past year.
CEO
Erez Israeli (56 yo)
6.8yrs
Tenure
₹197,090,000
Compensation
Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Chairman | 38.8yrs | ₹186.28m | 13.07% ₹ 132.0b | |
| Chairman of the Board & Member of the Management Council | 32.1yrs | ₹116.17m | 13.61% ₹ 137.4b | |
| CEO & Member of the Management Council | 6.8yrs | ₹197.09m | 0.039% ₹ 396.9m | |
| CFO & Member of the Management Council | less than a year | ₹48.82m | 0.0057% ₹ 57.2m | |
| Global Head of Quality and Pharmacovigilance & Member of the Management Council | 1.1yrs | ₹6.15m | no data | |
| CEO of API & Services & Member of Management Council | no data | ₹41.90m | 0.0027% ₹ 27.1m | |
| CEO of Branded Markets - India & Emerging Countries and Member of Management Council | no data | ₹82.74m | 0.016% ₹ 158.7m | |
| EVP, Head of Corporate Communications | 7.7yrs | ₹65.21m | 0.0063% ₹ 64.1m | |
| Executive VP | 7.5yrs | ₹66.05m | no data | |
| CEO of European Generics & Member of Management Council | no data | ₹63.09m | no data | |
| Global Head of Integrated Product Development Organisation & Member of the Management Council | no data | ₹55.63m | 0.000020% ₹ 201.9k | |
| Global Head – Biologics & Member of the Management Council | no data | ₹34.59m | no data |
6.8yrs
Average Tenure
56yo
Average Age
Experienced Management: DRREDDY's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Chairman | 38.8yrs | ₹186.28m | 13.07% ₹ 132.0b | |
| Chairman of the Board & Member of the Management Council | 32.1yrs | ₹116.17m | 13.61% ₹ 137.4b | |
| Member of the Scientific Advisory Board | no data | ₹8.36m | no data | |
| Independent Director | 2.5yrs | ₹18.77m | no data | |
| Independent Director | 6.1yrs | ₹13.34m | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 6.3yrs | ₹17.10m | no data | |
| Independent Director | 3.1yrs | ₹14.18m | no data | |
| Independent Director | 1.2yrs | ₹3.32m | no data | |
| Independent Director | 2.1yrs | ₹8.25m | no data | |
| Independent Director | 3.1yrs | ₹17.10m | no data | |
| Independent Director | 1.8yrs | ₹16.09m | no data |
3.1yrs
Average Tenure
64yo
Average Age
Experienced Board: DRREDDY's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 21:19 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 85 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |